No Data
Joinn Laboratories will provide Staidson Group with comprehensive pharmaceutical R&D services covering both non-clinical and clinical trial phases.
Joinn Laboratories (06127) announced that on December 20, 2024, the company entered into a framework agreement for Staidson's research and development services for 2025, which will be effective from January 1, 2025, to December 31, 2025. The company is required to provide the Staidson Group with comprehensive pharmaceutical research and development services covering non-clinical and clinical trial phases in accordance with the 2025 Staidson research and development services framework agreement. Due to the long-term cooperation with the Staidson Group, we are able to further expand into the pharmaceutical contract research organization service market and enhance our brand reputation, the Director believes that the 2025 Staidson research and development services framework agreement is in line with the company's strategy.
JOINN Laboratories Partners With Staidson for 2025 R&D Services
Joinn Laboratories (06127.HK) has entered into a research and development service agreement with Staidson for the year 2025.
On December 20, Gelonghui reported that Joinn Laboratories (06127.HK) announced that on December 20, 2024, the company entered into a 2025 research and development service framework agreement with Staidson, which will be effective from January 1, 2025, to December 31, 2025. The company is required to provide Staidson Group with comprehensive pharmaceutical research and development services covering non-clinical and clinical trial phases according to the 2025 Staidson research and development service framework agreement.
Shareholder Xiangtang Group has cumulatively reduced its shareholding by 23.5354 million shares.
Staidson (300204.SZ) announced that the company received a notification from the shareholder Xiangtang Group Co., Ltd. (referred to as "Xiangtang Group")...
Shu Taishen: Report for the third quarter of 2024
Staidson (300204.SZ) released its performance for the first three quarters, with a net loss of 9.365 million yuan.
Staidson (300204.SZ) released the report for the first three quarters of 2024, during the reporting period, the company achieved revenue of 2...
No Data
